Author(s):
Patil Mansi Balkrishna, Sulbha G Patil
Email(s):
mansipatil2289@gmail.com
DOI:
10.52711/0975-4377.2026.00035 
Address:
Patil Mansi Balkrishna1, Sulbha G Patil2
1P.S.G.V.P.M College of Pharmacy, Shahada, (Maharashtra) Dist - Nandurbar
2Assistant Professor, Department of Pharmaceutics, P.S.G.V.P.M College of Pharmacy, Shahada, (Maharashtra) Dist - Nandurbar.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Trazodone, a triazolopyridine antidepressant, is currently available only in oral dosage forms. Delivering this drug through the skin could help minimize adverse effects associated with high peak plasma levels and enhance patient compliance by reducing dosing frequency. This study aimed to assess how vehicle pH and permeation enhancers influence the ex-vivo permeation of trazodone through porcine skin, and design and optimize a transdermal delivery system containing trazodone hydrochloride. The findings indicate that the vehicle pH exerts a complex influence on trazodone skin permeation, as it affects both drug solubility and its partitioning into the skin. Additionally, fatty acids incorporated into the vehicle markedly increased permeation, with an enhancement factor of approximately 100. Transdermal drug delivery systems (TDDS) offer an alternative route for administering trazodone, an antidepressant with serotonin antagonist and reuptake inhibitor (SARI). By bypassing the gastrointestinal tract and first-pass hepatic metabolism, transdermal formulations can reduce systemic side effects, provide controlled and sustained drug release, and enhance therapeutic efficacy, particularly in patients with sleep disturbances or adherence challenges. Challenges in formulating trazodone for transdermal delivery include its molecular size, lipophilicity, and skin permeability. Recent research has explored permeation enhancers, novel polymeric matrices, and Microneedle-assisted delivery to optimize absorption. Overall, transdermal delivery of trazodone represents a promising approach to enhance clinical outcomes while minimizing adverse effects associated with oral administration.
Cite this article:
Patil Mansi Balkrishna, Sulbha G Patil. A Compressive Review on: Transdermal Delivery for Trazodone in Depression and Sleep Disorder. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):247-1. doi: 10.52711/0975-4377.2026.00035
Cite(Electronic):
Patil Mansi Balkrishna, Sulbha G Patil. A Compressive Review on: Transdermal Delivery for Trazodone in Depression and Sleep Disorder. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):247-1. doi: 10.52711/0975-4377.2026.00035 Available on: https://www.rjpdft.com/AbstractView.aspx?PID=2026-18-3-10
REFRENCES:
1. Jamaandi VG, Mulla JS, Vinay BL. Formulation and Evaluation of matrix- type transdermal patches of a Model antihypertensive drug. Asian Journal of Pharmaceutics. 2009; 8(1): 59-65.
2. Bagyalakshmi J, Vmshikrishna RP. Preparation, Optimization and in vitro & vivo evaluation of Membrane-moderated transdermal delivery of Ampicillin sodium. AAPS Pharm. Sci. Tech. 2008; 8(1): 50-55.
3. Prausnitz, M. R., Mitragotri, S., and Langer, R. Status and Future potential of transdermal drug Delivery. Nat. Rev. Drug Discov. 2004; 3: 115–124. Doi:10.1038/nrd1304.
4. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery System: a review. The Pharm Innovation. 2012; 1(4): 66-75.
5. SirishaV.N. L, Kirankumar P: Formulation and Evaluation of transdermal patches of propra-Nolol Hydrochloride, IOSR Journal of Pharmacy: 2012; 2(5): 31-37.
6. Sheth Nirav S. mistryRajan: Journal of Applied Pharmaceutical Science. 2011; 1(3): 96-101.
7. Yong Wang, Xiao-Ping Zhao and Jian-Wei Ruan. Transdermal Drug Delivery System of Aceclofenac for Rheumatoid Arthritis and the Effect of Permeation Enhancers: In vitro and in vivo Characterization. International Journal of Pharmacology. 2015; 11(5): 456-462
8. Keleb E, Sharma RK, Mosa EB, Aljahwi A AZ. Transdermal drug delivery system design and evaluation. Int J Adv Pharm Sci. 2010; 1: 201–11.
9. Bangale GS, Rathin Raj BS, Rajesh KS, Shinde GV, Umalkar DG, Rajveer CH, et al. Design and evaluation of transdermal films of Atenolol. J Chem Pharm Res. 2010; 2: 59604.
10. Shivaraj A, Selvam RP, Mani TT, Sivakumar T. Design and Evaluation of transdermal drug delivery of ketotifen fumarate. Int J Pharm Biomed Res. 2010; 1: 42–7.
11. Pandit V, Khanum A, Bhaskaran S, Banu V. Formulation and Evaluation of transdermal films for the treatment of overactive Bladder. Int J Pharm Tech Res. 2009; 1:799–804.
12. Nishad KM, Arul B, Rajasekaran S. Design and comparative Evaluation of clarithromycin gastric bioadhesive tablets by ex vivo and vivo methods. Asian J Pharm Clin Res. 2018; 11: 248–56.
13. Pandey S, Shah RR, Gupta A, Arul B. Design and evaluation of Buccoadhesive controlled release formulations of prochlorperazine Maleate. Int J Pharm Sci. 2016; 8: 3759.
14. Garala KC, Shinde AJ, Shah PH. Formulation and in vitro Characterization of monolithic matrix transdermal systems Using HPMC/Eudragit S 100 polymer blends. Int J Pharm Sci. 2009; 1: 108–20.